Diabetes News and Research

Latest Diabetes News and Research

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Experts try to fix problem of millions who don't adhere to prescriptions

The Boston Globe: "It is a common conundrum in doctor's offices, clinics, and hospitals across the nation: patients who do not take their medication as directed. It's true for people with high cholesterol, low calcium, diabetes, and asthma. It's even true for patients with the AIDS virus and those who have received life-saving replacement organs."

11 May 2010

People with family history of diabetes gain more weight

In the first study of its type, Australian researchers have shown that healthy people with a genetic predisposition to Type 2 diabetes gain more weight overeating over the short term than their non-genetically-prone counterparts.

11 May 2010

Iris Biotechnologies receives two new Canadian patents

Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, today announced two new Canadian patents.

11 May 2010

Synexus continues to grow in 2010 and beyond

During the first quarter of 2010 Synexus has seen growth in Germany reach thirty per cent as international sponsors take advantage of the additional patient reach the company can now offer following its acquisition of eight sites there as part of its takeover of Leipzig-based Clinpharm at the end of 2009.

From AES - Accelerated Enrollment Solutions 11 May 2010

Free health clinics still drawing large crowds in cities across U.S.

Parade: A series of no-cost health care clinics are making their way across America. In Atlanta 1,050 volunteers gave their time to serve uninsured Americans who needed medical care. "The Atlanta mega-clinic was the sixth in a series that began in September. (The first was held in Houston in partnership with TV talk-show host and cardiothoracic surgeon Dr. Mehmet Oz.)

11 May 2010

Genetic link to risk for diabetes and weight gain: New study

A recent study published in the international journal Diabetologia showed that Australians who eat too many high fat snacks tend to put on more weight if they have someone in their family with diabetes.

10 May 2010

Behavioral economics tested in new health law

The new health law contains "many opportunities to nudge people toward better health choices. … 'In healthcare, for years and years and years there's been an interest in changing provider and consumer behavior,'" says Stanford professor Alan Garber. "What's new is that money is flowing into research on behavioral economics, and the government is getting involved, Garber and others said.

10 May 2010

PositiveID reports $673,000 revenue for first-quarter 2010

PositiveID Corporation announced that it has reported financial results for the quarter ended March 31, 2010, its first full quarter of operations since its acquisition of Steel Vault Corporation in November 2009 and the resulting name change to PositiveID. The Company reported revenues of $673,000 for the first quarter of 2010, compared to revenues of $8,000 for the first quarter of 2009.

10 May 2010

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has achieved enrolled of over 400 subjects in its pivotal global Phase III study of its flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product designed to replace prandial injections of insulin.

10 May 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

Negative impact of depression on glycemic control in type 2 diabetes patients

In this German prospective representative study of patients with type 2 diabetes, baseline depression predicted problems with medication adherence, problems with health-related behaviors, and unsatisfactory glycemic control at follow-up.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Findings may help develop a new class of drugs for diabetes

More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that.

10 May 2010